This paper is in the following e-collection/theme issue:

Qualitative Methods (71) HIV/AIDS/STI Prevention and Care (879) Protocols for Public Health Research and Surveillance (69)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/47700, first published .
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Authors of this article:

Joyeeta Mukherjee1 Author Orcid Image ;   Shruta Rawat2 Author Orcid Image ;   Saif ul Hadi1 Author Orcid Image ;   Pritha Aggarwal1 Author Orcid Image ;   Venkatesan Chakrapani3 Author Orcid Image ;   Pratyasha Rath4 Author Orcid Image ;   Pallavi Manchi4 Author Orcid Image ;   Srikrishnan Aylur5 Author Orcid Image ;   Shelly Malhotra6 Author Orcid Image ;   Margaret Keane6 Author Orcid Image ;   Alok Gangaramany4 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

Joyeeta Mukherjee   1 , PhD ;   Shruta Rawat   2 , MSc ;   Saif ul Hadi   1 , MA ;   Pritha Aggarwal   1 , MSc ;   Venkatesan Chakrapani   3 , MD, PhD ;   Pratyasha Rath   4 , MA ;   Pallavi Manchi   4 , MA ;   Srikrishnan Aylur   5 , MBA ;   Shelly Malhotra   6 , MA ;   Margaret Keane   6 , MS, MBA ;   Alok Gangaramany   4 , MBA

1 International AIDS Vaccine Initiative, Gurugram, India

2 The Humsafar Trust, Mumbai, India

3 Centre for Sexuality and Health Research And Policy, Chennai, India

4 The Final Mile, Mumbai, India

5 Yeshwant Rao Gaitonde Centre for AIDS Research and Education, Chennai, India

6 International AIDS Vaccine Initiative, New York, NY, United States

Corresponding Author:

  • Joyeeta Mukherjee, PhD
  • International AIDS Vaccine Initiative
  • Unit no. 810, 8th Floor, Emaar Capital Tower - 1
  • Mehrauli Gurugram Road
  • Gurugram, 122002
  • India
  • Phone: 91 8588838927
  • Email: jmukherjee@iavi.org